Comprehensive Overview

The Group is a biopharmaceutical company with an integrated platform for product development and commercialization. It focuses on treatment areas that are rapidly developing in China but have not been met with medical needs, including tumors and severe infections. The Group mainly sells its own products on a daily basis, sells authorized products, and represents business partners in the sale and promotion of products in China. In recent years, the Group has also begun developing a variety of drugs under development.

Risk Factors

The Group's revenue is largely dependent on the mainland market, and it also sells its own product, Nitaxen, and promoted products from several business partners, including Falloda, Methotrexate, etc. The group's profitability will be influenced by the mainland market, policies, etc. If its pharmaceuticals are excluded from provincial or other government-funded medical insurance plans, it will have an impact on the group's business. In addition, mainland pricing laws and other policies aimed at reducing healthcare costs (such as volume procurement) may put pressure on group pricing and sales volume, and operations, revenue and profitability may be adversely affected.